$XFOR News

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital

X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate

Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now